Antithrombotic drug development for atrial fibrillation: Proceedings, Washington, DC, July 25-27, 2005

Keywords

MedicineWarfarinClinical trialAntithromboticAtrial fibrillationIntensive care medicineStroke (engine)Randomized controlled trialClinical PracticeSurgeryFamily medicineInternal medicine

Affiliated Institutions

Related Publications

Effect of Antihypertensive Treatment in Patients Having Already Suffered From Stroke

François Gueyffier , Jean‐Pierre Boissel , Florent Boutitie +10 more

Background and Purpose Drug treatment of high blood pressure has been shown to reduce the associated cardiovascular risk. Stroke represents the type of event more strongly linke...

1997 Stroke 247 citations

CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials

Kenneth F. Schulz , Douglas G. Altman , David Moher

The CONSORT statement is used worldwide to improve the reporting of randomised controlled trials. Kenneth Schulz and colleagues describe the latest version, CONSORT 2010, which ...

2010 BMC Medicine 13258 citations

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

Julie R. Brahmer , Christina Lacchetti , Bryan J. Schneider +26 more

Purpose To increase awareness, outline strategies, and offer guidance on the recommended management of immune-related adverse events in patients treated with immune checkpoint i...

2018 Journal of Clinical Oncology 3484 citations

National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000

Patricia J. Eifel , Jan Axelson , Janitha Costa +11 more

The panel concludes that decisions regarding adjuvant hormonal therapy should be based on the presence of hormone receptor protein in tumor tissues. Adjuvant hormonal therapy sh...

2001 JNCI Journal of the National Cancer I... 894 citations

Random Allocation in Observational Data

George Davey Smith

Conventional observational epidemiology has an unenviable reputation for generating false-positive findings,1,2 or "scares," as others call them.3 In 1993, for example, the New ...

2011 Epidemiology 47 citations

Publication Info

Year: 2008
Type: review
Volume: 155
Issue: 5
Pages: 829-840
Citations: 20
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Antithrombotic drug development for atrial fibrillation: Proceedings, Washington, DC, July 25-27, 2005

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

OpenAlex

Cite This

APA Style

                            
                                
                                    Kevin Jackson, 
                                
                                    Bernard J. Gersh, 
                                
                                    Norman Stockbridge
                                
                                et al.
                            
                            (2008). 
                            Antithrombotic drug development for atrial fibrillation: Proceedings, Washington, DC, July 25-27, 2005. 
                            American Heart Journal
                            , 155
                            (5)
                            , 829-840.
                            https://doi.org/10.1016/j.ahj.2008.01.023
                        

Identifiers

DOI: 10.1016/j.ahj.2008.01.023